Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Niagen Bioscience (NAGE) Enterprise Value: 2010-2025

Historic Enterprise Value for Niagen Bioscience (NAGE) over the last 14 years, with Sep 2025 value amounting to $679.8 million.

  • Niagen Bioscience's Enterprise Value rose 177.75% to $679.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $519.1 million, marking a year-over-year increase of 220.44%. This contributed to the annual value of $360.6 million for FY2024, which is 350.11% up from last year.
  • According to the latest figures from Q3 2025, Niagen Bioscience's Enterprise Value is $679.8 million, which was down 36.74% from $1.1 billion recorded in Q2 2025.
  • Niagen Bioscience's Enterprise Value's 5-year high stood at $1.1 billion during Q2 2025, with a 5-year trough of $70.8 million in Q3 2022.
  • Moreover, its 3-year median value for Enterprise Value was $234.5 million (2024), whereas its average is $328.7 million.
  • Its Enterprise Value has fluctuated over the past 5 years, first tumbled by 84.62% in 2022, then spiked by 502.57% in 2025.
  • Quarterly analysis of 5 years shows Niagen Bioscience's Enterprise Value stood at $227.2 million in 2021, then crashed by 53.93% to $104.7 million in 2022, then dropped by 23.47% to $80.1 million in 2023, then soared by 350.11% to $360.6 million in 2024, then soared by 177.75% to $679.8 million in 2025.
  • Its Enterprise Value stands at $679.8 million for Q3 2025, versus $1.1 billion for Q2 2025 and $480.9 million for Q1 2025.